SHOCKING: Dyne | Mind Blowing Facts

Dyne's Duchenne Drug Shows Strong Muscle And Function Improvements

Dyne Therapeutics, Inc. (NASDAQ:DYN) on Monday revealed topline results from the Registrational Expansion Cohort (REC) of its Phase 1/2 DELIVER trial evaluating zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251) for Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping.

Benzinga · Dec 8, 2025

These Analysts Lower Their Forecasts On Dyne Therapeutics Following Q2 Loss

Dyne Therapeutics Inc (NASDAQ:DYN) reported a loss for the second quarter on Monday.

Benzinga · Jul 29, 2025

Dyne is a New York jewellery brand fusing fluid forms with futuristic flair

Dyne embraces striking materials and silhouettes for very modern jewellery

Wallpaper · Dec 11, 2024